Is Nymox Pharmaceutical Corp halal to invest in?

According to Musaffa's Shariah screening methodology, Nymox Pharmaceutical Corp (NYMXF) is currently classified as NOT HALAL as of May 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Nymox Pharmaceutical Corp a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nymox Pharmaceutical Corp using these criteria to determine its compliance status.

Can Muslims buy shares of Nymox Pharmaceutical Corp?

Muslim investors may consider investing in Nymox Pharmaceutical Corp if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Nymox Pharmaceutical Corp classified as NOT HALAL?

Musaffa determines the Shariah status of Nymox Pharmaceutical Corp by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Nymox Pharmaceutical Corp updated?

The Shariah compliance status of Nymox Pharmaceutical Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Nymox Pharmaceutical Corp become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Nymox Pharmaceutical Corp?

You can check the latest Shariah compliance status of Nymox Pharmaceutical Corp on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NYMXF Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 05, 2025

Report Source: 2024 3rd Quarter Report

Nymox Pharmaceutical Corp. Stock Analysis NYMXF

United States Health Care Nano Cap Report: Q3, 2024

Nymox Pharmaceutical Corp. engages in the research and development of products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The firm also has a patent portfolio covering its marketed products, its investigational drugs, as well as other therapeutic and diagnostic indications. The company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. The company is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including second-hand smoke.

Key Statistics of Nymox Pharmaceutical Corp (NYMXF)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.05$0.06

Today's Open

$0.05

Volume

32.00K

P/E Ratio (TTM)

52 Week Range

$0.03$0.15

Market Cap

6.77M

Avg. Volume

23.88K

Dividend Yield

Financial Metrics & Statements of Nymox Pharmaceutical Corp (NYMXF)

FAQ's for Nymox Pharmaceutical Corp (NYMXF)

According to Musaffa’s Shariah screening methodology, Nymox Pharmaceutical Corp (NYMXF) is currently classified as NOT HALAL as of May 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.